China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the US Food and Drug Administration (FDA) to initiate a clinical study for its mRNA-based shingles vaccine. This marks a significant milestone in the company’s efforts to develop innovative vaccine solutions for global markets.
Pre-Clinical Study Results
In pre-clinical studies, the mRNA-based shingles vaccine demonstrated significant superiority compared to the listed recombinant subunit control vaccine. Third-party testing revealed enhanced specific T-cell immunity, higher specific IgG antibody titers, and improved membrane antigen fluorescent antibody (FAMA) titers. These results highlight the potential of AIM Vaccine’s candidate to offer enhanced protection against shingles.-Fineline Info & Tech
Leave a Reply